이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

국소 발병 발작이 있는 성인의 세노바메이트 (BLESS)

2026년 11월 10일 업데이트: Aziende Chimiche Riunite Angelini Francesco S.p.A

국소 발병 발작이 있는 성인의 Cenobamate: 실제 다기관 관찰 이탈리아어

The BLESS Study contributes to filling this information gap by collecting data from the Italian clinical practice and the Compassionate Use Program, to better characterize the clinical profile of cenobamate describing its effectiveness, safety and tolerability in adult patients diagnosed with uncontrolled focal epilepsy despite the use of at least two antiepileptic medicinal products.

연구 개요

상태

완전한

상세 설명

The main objective of the study is to describe the effectiveness of adjunctive cenobamate treatment in adult patients with uncontrolled focal epilepsy in Italy, overall and according to age class, setting of cenobamate treatment, cenobamate final target daily dose prescribed, and number of concomitant Anti Seizure Medications (ASMs). This will be assessed by intra-patient percent change and achievement of a ≥50% reduction in the seizure frequency from the pre-treatment baseline over a period of 52 weeks.

연구 유형

관찰

등록 (실제)

936

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

    • Bari
      • Bari, Bari, 이탈리아, 70124
        • Policlinico di Bari
    • Catanzaro
      • Catanzaro, Catanzaro, 이탈리아, 88100
        • Università degli Studi di Catanzaro "Magna Graecia"
    • Isernia
      • Pozzilli, Isernia, 이탈리아, 86077
        • IRCCS Neuromed
    • Pavia
      • Pavia, Pavia, 이탈리아, 27100
        • Fondazione Istituto Neurologico Casimiro Mondino
    • Roma
      • Roma, Roma, 이탈리아, 00128
        • Campus Bio-Medico
      • Roma, Roma, 이탈리아, 00161
        • Policlinico Umberto I
    • Torino
      • Torino, Torino, 이탈리아, 10153
        • Humanitas Gradenigo
    • Treviso
      • Conegliano, Treviso, 이탈리아, 31015
        • Associazione La Nostra Famiglia - IRCCS Eugenio Medea
    • Udine
      • Udine, Udine, 이탈리아, 33100
        • Azienda Sanitaria Universitaria (A.O.U.) Integrata
    • Vicenza
      • Vicenza, Vicenza, 이탈리아, 36100
        • Ospedale San Bortolo

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

샘플링 방법

확률 샘플

연구 인구

Adult patients diagnosed with focal epilepsy uncontrolled despite the use of at least two antiepileptic medicinal products, treated with adjunctive cenobamate in Italy. A single cohort of patients will be involved in the study, enrolling both subjects who initiated cenobamate treatment in accordance with the current clinical practice, and subjects previously included in the cenobamate Compassionate Use Programme in Italy, provided that they fulfil all of the eligibility criteria listed below

설명

Inclusion Criteria:

  • Age ≥18 years at the time of cenobamate treatment initiation
  • Male or female patients
  • Patients diagnosed with focal epilepsy uncontrolled despite a history of treatment with at least two antiepileptic medicinal products at the time of cenobamate treatment initiation in agreement with the Summary of Product Characteristics (SmPC)
  • Patients who at enrolment had received at least 12 weeks (titration period up to the initial recommended target dose of 200 mg daily completed) but no more than 52 weeks of cenobamate as adjunctive treatment of focal-onset seizures with or without secondary generalization
  • Patients with available retrospective data in medical charts and seizure diaries, including information about baseline seizure frequency prior to cenobamate treatment initiation
  • Patients who gave written informed consent to take part into the study and personal data processing consent following local regulation.
  • Patients who received adjunctive cenobamate for at least 12 weeks and discontinued permanently treatment before enrolment will also be included in the study-

Exclusion Criteria:

  • Patients diagnosed with familial short-QT syndrome
  • Patients affected by hypersensitivity to the active substance cenobamate or to any of the excipients (e.g., lactose monohydrate)
  • Patients with history of severe drug-induced hypersensitivity reaction, including (but not limited to) drug reaction with eosinophilia and systemic symptoms (DRESS), and Stevens Johnson syndrome
  • Patients enrolled in a clinical trial in which treatments for epilepsy are managed through a study protocol
  • Patient unable to read and write in Italian language and to autonomously fill in questionnaires and scales
  • Patients with a known pregnancy or who are breast-feeding from cenobamate treatment initiation till enrolment visit.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 관찰 모델: OTHER
  • 시간 관점: PROSPECTIVE

코호트 및 개입

그룹/코호트
Adult patients diagnosed treated with adjunctive cenobamate in Italy.

Adult patients diagnosed with focal epilepsy uncontrolled despite the use of at least two antiepileptic medicinal products, treated with adjunctive cenobamate in Italy.

A single cohort of patients will be involved in the study, enrolling both subjects who initiated cenobamate treatment in accordance with the current clinical practice, and subjects previously included in the cenobamate Compassionate Use Programme in Italy, provided that they fulfil all of the eligibility criteria listed below

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Absolute frequency of patients achieving a 50 % or greater reduction in the seizure frequency (overall)
기간: 12, 24 and 52 weeks of cenobamate treatment initiation

Seizure frequency during the baseline and post-baseline assessments was calculated by summing the total number of seizures (all types of seizures) reported in each considered period and dividing by the duration of that period (number of days), excluding days with no available diary data, and multiplying by 28 to normalize to a monthly rate ("monthly seizure frequency").

12, 24 and 52 weeks of cenobamate treatment initiation
Relative frequency of patients achieving a ≥50% (50% or greater) reduction in the seizure frequency (overall)
기간: 12, 24 and 52 weeks of cenobamate treatment initiation

Seizure frequency during the baseline and post-baseline assessments was calculated by summing the total number of seizures (all types of seizures) reported in each considered period and dividing by the duration of that period (number of days), excluding days with no available diary data, and multiplying by 28 to normalize to a monthly rate ("monthly seizure frequency").

12, 24 and 52 weeks of cenobamate treatment initiation
Intra-patient percent change in the seizure frequency (overall)
기간: 12, 24 and 52 weeks of cenobamate treatment initiation

Intra-patient percent change from baseline will be defined as [(monthly seizure frequency at post-baseline assessments - monthly seizure frequency at baseline), divided by the monthly seizure frequency at baseline] multiplied by 100.

12, 24 and 52 weeks of cenobamate treatment initiation
Absolute frequency of patients achieving a 50 % or greater reduction in the seizure (stratified)
기간: 12, 24 and 52 weeks of cenobamate treatment initiation

Seizure frequency during the baseline and post-baseline assessments was calculated by summing the total number of seizures (all types of seizures) reported in each considered period and dividing by the duration of that period (number of days), excluding days with no available diary data, and multiplying by 28 to normalize to a monthly rate ("monthly seizure frequency").

Population will be stratified according to the following:

  • Age class of patient at the time of cenobamate treatment initiation (i.e., <65 years; ≥65 years).
  • Setting of cenobamate treatment initiation (i.e., CUP; current clinical practice).
  • Cenobamate final target daily dose prescribed (i.e., 200 mg; >200 mg).
  • Number of ASMs concomitant with cenobamate (i.e., ≤2 ASMs; >2 ASMs).
12, 24 and 52 weeks of cenobamate treatment initiation
Relative frequency of patients achieving a ≥50% (50% or greater) reduction in the seizure frequency (stratified)
기간: 12, 24 and 52 weeks of cenobamate treatment initiation

Seizure frequency during the baseline and post-baseline assessments was calculated by summing the total number of seizures (all types of seizures) reported in each considered period and dividing by the duration of that period (number of days), excluding days with no available diary data, and multiplying by 28 to normalize to a monthly rate ("monthly seizure frequency").

Population will be stratified according to the following:

  • Age class of patient at the time of cenobamate treatment initiation (i.e., <65 years; ≥65 years).
  • Setting of cenobamate treatment initiation (i.e., CUP; current clinical practice).
  • Cenobamate final target daily dose prescribed (i.e., 200 mg; >200 mg).
  • Number of ASMs concomitant with cenobamate (i.e., ≤2 ASMs; >2 ASMs).
12, 24 and 52 weeks of cenobamate treatment initiation
Intra-patient percent change in the seizure frequency (stratified)
기간: 12, 24 and 52 weeks of cenobamate treatment initiation

Intra-patient percent change from baseline will be defined as [(monthly seizure frequency at post-baseline assessments - monthly seizure frequency at baseline), divided by the monthly seizure frequency at baseline] multiplied by 100.

Population will be stratified according to the following:

  • Age class of patient at the time of cenobamate treatment initiation (i.e., <65 years; ≥65 years).
  • Setting of cenobamate treatment initiation (i.e., CUP; current clinical practice).
  • Cenobamate final target daily dose prescribed (i.e., 200 mg; >200 mg).
  • Number of ASMs concomitant with cenobamate (i.e., ≤2 ASMs; >2 ASMs).
12, 24 and 52 weeks of cenobamate treatment initiation

2차 결과 측정

결과 측정
측정값 설명
기간
Absolute frequency of patients achieving a ≥50%/≥75%/≥90%/=100% sustained reduction in the seizure frequency
기간: 24 and 52 weeks of cenobamate treatment initiation.

Sustained seizure frequency reduction will be defined as a ≥50%/≥75%/≥90%/=100% reduction in baseline seizure frequency achieved at 12 weeks of cenobamate treatment initiation, that continues (is sustained) without interruption and without cenobamate permanent discontinuation through the observation period until 24 and 52 weeks of cenobamate treatment initiation, respectively.

24 and 52 weeks of cenobamate treatment initiation.
Absolute frequency of patients achieving a ≥75%/≥90%/=100% reduction in the seizure frequency
기간: 12, 24 and 52 weeks of cenobamate treatment initiation.

Seizure frequency reduction will be defined as a ≥75%/≥90%/=100% reduction in baseline seizure frequency achieved at 12, 24 and 52 weeks of cenobamate treatment initiation, respectively.

12, 24 and 52 weeks of cenobamate treatment initiation.
Relative frequencies of patients achieving a ≥50%/≥75%/≥90%/=100% sustained reduction in the seizure frequency
기간: 24 and 52 weeks of cenobamate treatment initiation.

Sustained seizure frequency reduction will be defined as a ≥50%/≥75%/≥90%/=100% reduction in baseline seizure frequency achieved at 12 weeks of cenobamate treatment initiation, that continues (is sustained) without interruption and without cenobamate permanent discontinuation through the observation period until 24 and 52 weeks of cenobamate treatment initiation, respectively

24 and 52 weeks of cenobamate treatment initiation.
Relative frequencies of patients achieving a ≥75%/≥90%/=100% reduction in the seizure frequency
기간: 12, 24 and 52 weeks of cenobamate treatment initiation.

Seizure frequency reduction will be defined as a ≥75%/≥90%/=100% reduction in baseline seizure frequency achieved at 12, 24 and 52 weeks of cenobamate treatment initiation.

12, 24 and 52 weeks of cenobamate treatment initiation.
Absolute frequency of patients with at least one AE
기간: Through study completion, an average of 1 year

Absolute frequency of patients treated with cenobamate who experienced at least one AE during the applicable observation period

Through study completion, an average of 1 year
Relative frequency of patients with at least one AE
기간: Through study completion, an average of 1 year

Relative frequency of patients treated with cenobamate who experienced at least one AE during the applicable observation period

Through study completion, an average of 1 year
Absolute frequency of patients with at least one ADR
기간: Through study completion, an average of 1 year

Absolute frequency of patients treated with cenobamate who experienced at least one ADR during the applicable observation period

Through study completion, an average of 1 year
Relative frequency of patients with at least one ADR
기간: Through study completion, an average of 1 year

Relative frequency of patients treated with cenobamate who experienced at least one ADR during the applicable observation period

Through study completion, an average of 1 year
Absolute frequency of patients treated with at least one SAE
기간: Through study completion, an average of 1 year

Absolute frequency of patients treated with at least one SAE during the applicable observation period

Through study completion, an average of 1 year
Relative frequency of patients treated with at least one SAE
기간: Through study completion, an average of 1 year

Relative frequency of patients treated with at least one SAE during the applicable observation period

Through study completion, an average of 1 year
Health-Related Quality of life (HRQoL)
기간: 12, 24 and 52 weeks

The Health-Related Quality of life (HRQoL) of patients will be assessed by means of the 31-item Quality Of Life In Epilepsy inventory (QOLIE-31).

The 31-item Quality Of Life In Epilepsy inventory (QOLIE-31) is a patient self-reported instrument that contains 31 items grouped in seven multi-item scales ( "seizure worry", "overall QoL", "emotional well-being", "energy fatigue", "cognitive functioning", "medication effects" and "social functioning"). Different items in the QOLIE-31 have different ranges of precoded numeric values, so the scoring procedure requires conversion from raw, precoded numeric values to scores of 0-100 points, with higher scores reflecting better quality of life. The QOLIE-31 overall score is calculated by summing the product of each scale score times its weight and summing over all scales, according to the instructions obtained from copyright holders.

12, 24 and 52 weeks
Patient Global functioning (CGI-S)
기간: 12, 24 and 52 weeks

The patient global functioning will be assessed by means of the Clinical Global Impression (CGI) Scales. The Early Clinical Drug Evaluation Program (ECDEU) version of the CGI is a 3-item clinician rated scale that measures illness severity (CGI-S), global improvement or change (CGI-I) and treatment response (efficacy index: CGI-E).

The CGI-S score ranges from 1 (normal) through to 7 (amongst the most severely ill patients).

The calculation of the scores will be performed according to the instructions obtained from copyright holders.

12, 24 and 52 weeks
Patient Global functioning (CGI-I)
기간: 12, 24 and 52 weeks

The patient global functioning will be assessed by means of the Clinical Global Impression (CGI) Scales. The Early Clinical Drug Evaluation Program (ECDEU) version of the CGI is a 3-item clinician rated scale that measures illness severity (CGI-S), global improvement or change (CGI-I) and treatment response (efficacy index: CGI-E).

The CGI-I score ranges from 1 (very much improved) through to 7 (very much worse).

The calculation of the scores will be performed according to the instructions obtained from copyright holders.

12, 24 and 52 weeks
Patient Global functioning (CGI-E)
기간: 12, 24 and 52 weeks

The patient global functioning will be assessed by means of the Clinical Global Impression (CGI) Scales. The Early Clinical Drug Evaluation Program (ECDEU) version of the CGI is a 3-item clinician rated scale that measures illness severity (CGI-S), global improvement or change (CGI-I) and treatment response (efficacy index: CGI-E).

The CGI-E score should take account of both therapeutic effect and tolerance, and ranges from 0 (marked improvement and no toxicity) and 4 (unchanged or worse and toxicity outweigh the therapeutic effects). Each component of the CGI is rated separately; the instrument does not yield a global score.

The calculation of the scores will be performed according to the instructions obtained from copyright holders.

12, 24 and 52 weeks
Daytime Sleepiness
기간: 12, 24 and 52 weeks

Daytime Sleepiness will be assessed by means of the Epworth Sleepiness Scale (ESS). The ESS is a self-administered questionnaire with 8 questions. Respondents are asked to rate, on a 4-point scale (0-3), their usual chances of dozing off or falling asleep while engaged in eight different daily activities. The ESS score can range from 0 to 24. The higher the ESS score, the higher that person Average Sleep Propensity in Daily Life (ASP), or their daytime sleepiness across a wide range of activities in their daily lives.

12, 24 and 52 weeks
Hospital Anxiety and Depression
기간: 12, 24 and 52 weeks

Anxiety and depression symptoms will be assessed by means of the the Hospital Anxiety and Depression Scale (HADS). This is a patient self-reported instrument consisting of 14 items that provide scores on two specific subscales: "Anxiety" subscale (HADS-A, 7 items) and "Depression" subscale (HADS-D, 7 items).

All items were scored on a 4-point Likert scale from 0 ("never") to 3 ("almost every day") referring to overt symptoms within the last week. Total scores range from 0 to 21 points for each subscale, with higher scores indicating higher levels of symptoms.

12, 24 and 52 weeks
Retention with cenobamate
기간: 52 weeks

Retention with cenobamate will be assessed by calculating the frequency of patients still on treatment with cenobamate at 52 weeks of treatment initiation.

52 weeks

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2023년 1월 24일

기본 완료 (실제)

2025년 12월 30일

연구 완료 (실제)

2026년 10월 21일

연구 등록 날짜

최초 제출

2023년 4월 26일

QC 기준을 충족하는 최초 제출

2023년 5월 5일

처음 게시됨 (실제)

2023년 5월 16일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 13일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 10일

마지막으로 확인됨

2026년 11월 1일

추가 정보

이 연구와 관련된 용어

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다